Literature DB >> 20716846

The role of MEKK1 in hypertrophic cardiomyopathy.

John P Konhilas1, Dana M Boucek, Todd R Horn, Gary L Johnson, Leslie A Leinwand.   

Abstract

MEKK1 is a ubiquitously expressed mitogen activated protein kinase that is involved in tissue remodeling in a variety of settings including carotid artery blood flow cessation, wound healing, and breast adenocarcinoma intravasation. Here, we have tested the function of MEKK1 in genetic hypertrophic cardiomyopathy (HCM). MEKK1 was genetically deleted in C57Bl6/J mice expressing a mutant alpha-myosin heavy chain (HCM-MEKK1(-/-)). The absence of MEKK1 in HCM resulted in a more pronounced hypertrophy when compared to HCM mice with the MEKK1 gene intact without further increases in atrial natriuretic factor and beta-myosin heavy chain (MyHC) expression and fibrosis. Since MEKK1 is required for the induction of several tissue proteases, we tested the hypothesis that cardiac enlargement of HCM- MEKK1(-/-) mice was due to altered expression of urokinase-type plasminogen activator (uPA), JunB, matrix-metalloproteinase (MMP), and tissue inhibitors of MMPs (TIMPs). Because of its role in preventing apoptosis, we also tested the loss of MEKK1 on apoptotic mediators Bcl-2, cytochrome C, caspase-9, and caspase-3. uPA expression was decreased while JunB, MMP-9, caspase-9, and caspase-3 activities were elevated in HCM- MEKK1(-/-) hearts when compared to MEKK1(-/-), wild-type (WT), and HCM mice. Bcl-2 and Cyt C expression was elevated only in HCM mice. We conclude that the absence of MEKK1 induces a more pronounced cardiac hypertrophy to HCM through altered expression of proteases implicated in cardiac remodeling and increased apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716846      PMCID: PMC2975484          DOI: 10.1536/ihj.51.277

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  39 in total

Review 1.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy.

Authors:  J D Molkentin; G W Dorn
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

2.  MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation.

Authors:  T Yujiri; M Ware; C Widmann; R Oyer; D Russell; E Chan; Y Zaitsu; P Clarke; K Tyler; Y Oka; G R Fanger; P Henson; G L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

3.  Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3.

Authors:  Paul W M Fedak; Svetlana M Altamentova; Richard D Weisel; Nafiseh Nili; Nobuhisa Ohno; Subodh Verma; Tsu-Yee J Lee; Chris Kiani; Donald A G Mickle; Bradley H Strauss; Ren-Ke Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-10-10       Impact factor: 4.733

4.  Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy.

Authors:  M C Olsson; B M Palmer; L A Leinwand; R L Moore
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-03       Impact factor: 4.733

5.  A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.

Authors:  F G Spinale; M L Coker; L J Heung; B R Bond; H R Gunasinghe; T Etoh; A T Goldberg; J L Zellner; A J Crumbley
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

6.  MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.

Authors:  Tetsuo Minamino; Toshiaki Yujiri; Naohiro Terada; George E Taffet; Lloyd H Michael; Gary L Johnson; Michael D Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.

Authors:  Junichi Sadoshima; Olivier Montagne; Qian Wang; Guiping Yang; Jill Warden; Jing Liu; Gen Takagi; Vijaya Karoor; Chull Hong; Gary L Johnson; Dorothy E Vatner; Stephen F Vatner
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 8.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

Authors:  Francis G Spinale
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

9.  MEKK1 is required for inducible urokinase-type plasminogen activator expression.

Authors:  James Witowsky; Amy Abell; Nancy Lassignal Johnson; Gary L Johnson; Bruce D Cuevas
Journal:  J Biol Chem       Date:  2002-12-17       Impact factor: 5.157

10.  Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.

Authors:  Julian C Braz; Orlando F Bueno; Qiangrong Liang; Benjamin J Wilkins; Yan-Shan Dai; Stephanie Parsons; Joseph Braunwart; Betty J Glascock; Raisa Klevitsky; Thomas F Kimball; Timothy E Hewett; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

View more
  2 in total

1.  Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.

Authors:  Lu Gao; Rui Yao; Yuzhou Liu; Zheng Wang; Zhen Huang; Binbin Du; Dianhong Zhang; Leiming Wu; Lili Xiao; Yanzhou Zhang
Journal:  Mol Cell Biochem       Date:  2017-02-07       Impact factor: 3.396

2.  Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.

Authors:  Stephen W Luckey; Chris D Haines; John P Konhilas; Elizabeth D Luczak; Antke Messmer-Kratzsch; Leslie A Leinwand
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.